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Introduction | The SARS-CoV-2 virus responsible 
for severe respiratory infection associated with 
coronavirus infectious disease 2019 (COVID-19) was 
first identified and confirmed in Florida on March 1, 
2020. Between March 1, 2020 and June 4, 2020, 
60,183 persons in Florida were diagnosed with 
COVID-19 and 2,607 had COVID-19-associated 
mortality.1 Large-scale testing is one of the major 
pillars in Florida’s response efforts to detect and 
contain the transmission of COVID-19. As of June 4, 
2020, over 1,107,000 persons in Florida had been 
tested at public health, commercial and hospital 
laboratories; results indicated a state positivity rate of 
5.3 percent by RT-PCR and 3.6% positivity for 
initially tested persons with SARS-CoV-2, as some 
persons were retested to determine if virus was still 
present.  
Following the first persons diagnosed with SARS-
CoV-2 in Florida, State Surgeon General Scott 
Rivkees declared a Public Health Emergency on 
March 1st. This was closely followed by a State of 
Emergency declared by Governor Ron DeSantis who 
issued statewide stay at home orders with guidance to 
practice social distancing and other prevention 
measures in accordance with national guidelines.2-4 As 
of June 4, 2020, all 67 of Florida’s counties had 
confirmed cases, with Miami-Dade County having the 
highest test positivity rate (10%) and 32 percent of 
total cases statewide.1 Other top metropolitan counties 
with substantial disease burden included Broward (6% 
positivity, 12% of total cases), Palm Beach (8% 
positivity, 11% of total cases), Hillsborough (4% 
positivity, 4% of total cases), Orange (3% positivity, 
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the covariates age, sex, race/ethnicity, and testing location. Results and Discussion: 
As of June 3, 2020, of 5,779 healthcare workers and first responders tested, 4.1% were 
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positive for persons testing at the Miami Hard Rock Stadium (aOR 2.24 [95% C.I. 
1.48-3.39]), persons of Haitian/Creole ethnicity (aOR 3.28 [95% C.I. 1.23-8.72]), 
Hispanic/Latino(a) ethnicity (aOR 2.17 [95% C.I. 1.50-3.13], and Black non-Hispanic 
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ethnicity and by testing location. 
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4% of total cases), and Duval counties (3% positivity, 
3% of total cases).  
 
As the incidence of COVID-19 increased across 
Florida, demand for SARS-CoV-2 virus testing also 
grew exponentially, leading to the establishment of 
state-wide drive-thru testing operations via 
partnerships between the Department of Health, 
Division of Emergency Management, and the National 
Guard. These testing strategies improved and provided 
direct and easy access to diagnostic testing to reach the 
broader population. Drive-through testing formats had 
previously been touted as a safe and effective method 
for large volume testing initiatives that directly detect 
the pathogen during pandemic situations and have the 
benefit of reducing the number of infectious persons 
entering and contaminating healthcare establishments 
as well as promoting social distancing.5,6  
 
Approximately two months after the initial cases were 
identified in Florida, point-of-care (POC) SARS-CoV-
2 antibody testing was offered to healthcare workers 
and first responders at five drive-through COVID-19 
testing locations to assess the seroprevalence of 
antibodies against the SARS-CoV-2 circulating in the 
Florida population. Antibody testing has been used in 
many diseases previously to track and understand 
seroprevalence of disease including Zika virus and 
dengue.7-9 For COVID-19, antibody testing can also be 
used to identify asymptomatic individuals or 
individuals who may have developed mild illness that 
didn’t lead to testing, and identify potential donors of 
convalescent plasma that could be used to treat 
critically ill patients, as the plasma contains antibodies 
to COVID-19.10-12 Several SARS-CoV-2 antibody 
seroprevalence studies were conducted previously in 
the United States, and only one so far has focused on 
healthcare workers.13-18 These previous studies 
indicated that rates of infection were higher than rates 
of reported persons with SARS-CoV-2, likely due to 
mild disease and asymptomatic infections that were 
undetected, including one study identifying an 
antibody seropositivity of nearly 2% in South Florida 
in April 2020.14-16  
 
The purpose of this study was to determine the 
seroprevalence of COVID-19 in healthcare workers 
and first responders at five drive-thru testing sites in 
Florida from May 6 through June 3, 2020, using a POC 
SARS-CoV-2 antibody test. This report describes the 
multi-agency collaborative partnerships and actions 
taken to integrate POC antibody testing at established 
large-scale COVID-19 testing sites. Further, this study 
provided an opportunity to establish a baseline 
seroprevalence amongst high-risk, front-line workers 
during the COVID-19 emergency response in Florida 
and describes racial/ethnic disparities within and 
amongst those tested across the five locations in the 
state. 
 
Methods | On May 6, 2020, the Florida Department of 
Health in conjunction with community partners, the 
Florida National Guard, nurses, paramedics, and 
emergency medical technicians, set-up POC antibody 
testing at Miami Hard Rock Stadium as part of an 
ongoing SARS-CoV-2 drive-thru testing mission, that 
previously focused on virologic testing only. Antibody 
testing was expanded to three additional drive-thru 
sites (Jacksonville, Orlando, and Palm Beach) on May 
9, 2020 and one final site, Miami Beach Convention 
Center, on May 21, 2020. At each of these five sites, 
persons arriving at these testing locations were pre-
screened and occupation-verified to determine if they 
were healthcare workers or first responders. Triaged 
healthcare workers and first responders were given the 
option to be tested for SARS-CoV-2 antibody, along 
with SARS-CoV-2 viral testing via real time, reverse-
transcription-polymerase chain reaction (rRT-PCR). 
All participants tested provided verbal consent. From 
May 6, 2020 through June 3, 2020 these testing sites 
provided SARS-CoV-2 antibody testing solely to 
healthcare workers and first responders. On June 4, 
2020, these testing locations expanded antibody 
testing to all persons. 
 
All healthcare workers and first responders tested for 
SARS-CoV-2 antibodies completed a laboratory 
specimen collection form for the POC serologic test 
prior to testing. Data captured on the form included 
demographic information such as sex at birth, race, 
ethnicity, date of birth, and test result. Healthcare 
workers and first responders had whole blood 
specimens drawn via venipuncture while they 
remained in their vehicles. Specimens were processed 
according to manufacturer’s specifications using the 
Cellex Inc. qSARS-CoV-2 IgG/IgM Rapid Test.19 The 
tests uses SARS-CoV-2 recombinant antigens (S and 
N proteins). The Cellex Inc. qSARS-CoV-2 IgG/IgM 
Rapid Test reports a percent positive agreement to RT-
PCR SARS-CoV-2 samples of 93.8% (95% C.I. 88.2-
96.8%) and negative percent agreement of 96.0% 
(95% C.I. 92.8-97.8%). Specimen processing was 
done onsite and results were returned to participants in 
less than one half hour. Test results were subsequently 
entered into the Florida Department of Health’s 
Counseling Testing and Linkage System (CTLS). 
 
SARS-CoV-2 antibody testing data from these five 
drive-thru sites from May 6, 2020 through June 3, 
2020 were extracted on June 7, 2020 from CTLS. Test 
results were recorded as IgM+, IgM+ and IgG+, IgG+, 
positive, negative, or three different results that were 
combined as “unknown” in CTLS (invalid, 
indeterminate, missing/result in progress). When 
analyzing by individual rather than by site we 
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combined all possible positive (IgM+, IgM+ and 
IgG+, IgG+, and positive) results into one positive 
category. Age groups started with 17-29, followed by 
10-year age groups up to 69 years of age, and one 
collapsed age group of 70-89 years because there were 
no positive antibody tests in the 80-89 (n=8) age 
group. Race and ethnicity were combined. Ethnicity 
took prioritization as persons with Haitian/Creole or 
Hispanic/Latino(a) ethnicity were categorized as such 
regardless of selection on the race variable (i.e. White 
non-Hispanic was categorized as Hispanic/Latino(a)). 
Persons selecting White for “race” and “non-
Hispanic” or “missing” for ethnicity were classified as 
White non-Hispanic. Likewise, persons selecting 
Black for “race” and “non-Hispanic” or “missing” for 
ethnicity were classified as Black non-Hispanic. 
Persons selecting any other race/ethnicity beyond 
these categories listed were classified as “Other”, 
while those selecting none were listed as 
missing/unknown. 
 
SARS-CoV-2 antibody test results were stratified by 
test site and specimen collection date. Antibody 
seropositivity was determined by taking the sum of all 
positive test results (IgM+, IgM+ and IgG+, IgG+, and 
positive) and dividing by total number of test results. 
We determined seropositivity for healthcare workers 
and first responders.  Odds ratios for the seropositivity 
for healthcare workers and first responders were 
estimated for sex, race/ethnicity, age group, and 
testing location. These odds ratios were adjusted for 
testing location (table 2) as well as other demographics 
(supplemental table 1) using logistic regression with 
Wald’s 95% confidence intervals. All analyses were 
performed using SAS Studio v. 3.6 (Cary, N.C.). The 
project was reviewed by the Florida Department of 
Health Institutional Review Board Office and was 
conducted consistent with applicable federal law and 
institutional policies.20  
 
Results | Testing began at Miami Hard Rock Stadium 
on May 6, 2020 with 47 tests including 5 that were 
reactive (1 IgM+ and 4 IgG+) (Figure 1). Testing 
seropositivity peaked the next day on May 7, 2020 at 
11.1% (8 of 72). When testing capacity expanded to 
three additional sites on May 9, 2020: Jacksonville, 
Orlando, and Palm Beach, testing peaked on May 12, 
2020 with 358 healthcare workers and first responders 
tested. The fifth and final site, the Miami Beach 
Convention Center, began testing healthcare workers 
and first responders on May 21, 2020. On June 4, 
2020, these sites stopped limiting testing to healthcare 
workers and first responders and were opened to 
others.  
 
Figure 1. Cumulative point-of-care (POC) antibody tests performed across all sites by day and corresponding daily 
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Table 1. Summary of point-of-care (POC) antibody test results stratified by testing site, Florida, May-June 2020 
 
 Antibody Test Result   
Testing Site IgM+ IgM & IgG+ IgG+ Positive Negative Non-resulted Total 
% Positive 
(95% CI)* 
Miami-Hard Rock Stadium 3 5 100 7 1295 18 1428 8.2% (6.7-9.6) 
Orlando-Orange County C.C. 5 4 41 0 1734 13 1797 2.8% (2.0-3.6) 
Jacksonville-TIAA Bank Field 3 4 36 4 1703 28 1778 2.7% (1.9-3.4) 
Palm Beach-FITTEAM Ballpark 0 0 9 3 448 31 491 2.6% (1.2-4.1) 
Miami Beach Convention Center 1 0 9 0 272 3 285 3.5% (1.4-5.7) 
All Sites 12 13 195 14 5452 93 5779 4.1% (3.6-4.6) 







Table 2. Point-of-care (POC) antibody test results by persons stratified by demographics and adjusted for testing 
location, Florida, May-June 2020 
 
Demographics Positive Negative % Positive (95% CI)* Odds Ratio (95% CI) adj Odds Ratio (95% CI)† 
Sex at Birth      
   Female 134 3169 4.1% (3.4-4.8) 1.00 (0.76, 1.32) 1.09 (0.83-1.44) 
   Male 90 2134 4.0% (3.3-5.0) Ref Ref 
   Missing‡ 10 149 6.3% (3.3-11.3) N/A N/A 
Race/Ethnicity      
   White non-Hispanic 63 2626 2.3% (1.8-3.0) Ref Ref 
   Black non-Hispanic 40 877 4.4% (3.2-5.9) 1.90 (1.27-2.85) 1.63 (1.08-2.46) 
   Hispanic/Latino(a) 87 1230 6.6% (5.4-8.1) 2.95 (2.12-4.11) 2.17 (1.50-3.13) 
   Haitian/Creole 5 49 9.3% (3.6-20.3) 4.25 (1.64-11.04) 3.28 (1.23-8.72) 
   Other¶ 11 316 3.4% (1.8-6.0) 1.45 (0.76-2.78) 1.53 (0.80-2.95) 
   Missing‡ 16 365 4.2% (2.6-6.8) N/A N/A 
Age group (years)      
   17-29 34 674 4.8% (3.4-6.7) Ref Ref 
   30-39 48 1412 3.3% (2.5-4.3) 0.67 (0.43-1.06) 0.67 (0.43-1.05) 
   40-49 46 1298 3.4% (2.6-4.5) 0.70 (0.44-1.11) 0.69 (0.44-1.09) 
   50-59 65 1282 4.8% (3.8-6.1) 1.00 (0.66-1.55) 0.96 (0.62-1.47) 
   60-69 31 633 4.7% (3.3-6.6) 0.97 (0.59-1.60) 0.94 (0.57-1.56) 
   70-89 9 109 7.6% (3.9-14.0) 1.64 (0.76-3.51) 1.67 (0.77-3.63) 
   Missing‡ 1 44 2.2% (0.0-12.6) N/A N/A 
Total‡ 234 5452 4.1% (3.6-4.7) N/A N/A 
* The sum of all positive results (IgM+, IgM & IgG+, IgG+, and positive) divided by the sum of that number and the 
negative results. † Odds ratio adjusted for testing site. ‡ Odds ratio and adjusted odds ratios not calculated for 
totals and missing demographic values. Non-resulted tests were excluded. ¶ Persons of other race/ethnicity were 
individuals who identified as either “other” as a race or identified as a different race/ethnicity not listed above. 
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In total, 5,779 SARS-CoV-2 POC antibody tests were 
performed among healthcare workers and first 
responders in Florida at five drive-thru testing sites 
from May 6, 2020 through June 3, 2020. Of the 5,686 
(98.4%) who had a reported result, 5,452 (95.9%) 
were negative and 234 (4.1%) were positive for 
SARS-CoV-2 antibodies. The highest SARS-CoV-2 
antibody positivity rate, 8.2%, was at the Miami Hard 
Rock Stadium. The remaining test sites had a 
seropositivity for SARS-CoV-2 ranging between 2.6% 
and 3.5%. Although more women than men were 
tested for SARS-CoV-2 antibodies, seropositivity 
(4.1% vs. 4.0%) did not differ by sex (Table 2). Test 
positivity ranged from 3.3% to 4.8% for persons aged 
17-69 years but for those aged 70-89 years it was 7.6% 
(9 of 118) (95% C.I. 3.9-14.0%). Seropositivity was 
higher for persons with Haitian/Creole ethnicity (9.3% 
95% C.I. 3.6-20.3%), Hispanic/Latino ethnicity (6.6% 
95% C.I. 5.4-8.1%), and Black non-Hispanic persons 
(4.4% 95% C.I. 3.2-5.9%) than for white non-Hispanic 
persons (2.3% 95% C.I. 1.8-3.0%).  
 
Even after accounting for the testing location, 
healthcare workers and first responders of 
Haitian/Creole ethnicity (aOR 3.28 95% C.I. 1.23-
8.72), Hispanic/Latino(a) ethnicity (aOR 2.17 95% 
C.I. 1.50-3.13), and Black non-Hispanic persons (aOR 
1.63 95% C.I. 1.08-2.46) had higher odds of testing 
positive for SARS-CoV-2 antibodies compared to 
white non-Hispanic persons (Table 2). Persons testing 
at the Miami Hard Rock Stadium had 2.2 (95% C.I. 
1.48-3.39) times higher odds of testing positive for 
SARS-CoV-2 antibodies than persons at other sites, 
after adjusting for age, race/ethnicity, and sex 
(supplemental table 1).   
 
Discussion | Seropositivity among healthcare workers 
and first responders was generally low in Florida in 
May 2020, averaging 4%; but at one site, the Miami 
Hard Rock Stadium, positivity was nearly 8%. This 
suggests disease transmission was widespread in 
Florida at that time but focally clustered in some 
geographic areas. However, this local variation in 
seropositivity did not differ greatly from the reported 
epidemiological burden of COVID-19 in Florida 
through June 3, 2020 although somewhat surprisingly, 
because the RT-PCR positivity was higher in the 
Counties at the same time, the Miami Beach and Palm 
Beach locations had seropositivity no different from 
those of Orlando and Jacksonville.1 When compared 
to a previous antibody study among South Floridians 
in April, the antibody test positivity from this study in 
May and June among healthcare workers in South 
Florida, particularly at the Hard Rock testing site, was 
higher than in previous study.16 Moreover, the 
seropositivity observed among healthcare workers and 
first responders in this study was similar to that of 
healthcare workers at locations across the country 
tested in a similar timeframe.18 After accounting for 
testing location, race/ethnicity disparities in 
seropositivity for SARS-CoV2 antibodies were 
observed among healthcare workers and first 
responders in this study similar to the disparities 
observed among healthcare workers and nationally.5,17 
 
One of the strengths of this evaluation was its scope 
and breadth in comparison to other antibody studies in 
the United States and around the world as it included 
more geographically diverse testing sites and more 
persons tested.13-18 Although healthcare workers and 
first responders are at potentially increased risk for 
SARS-CoV-2 infection, in Florida, their seropositivity 
for SARS-CoV-2 antibodies did not reach the levels 
observed in a small study in Boston (31.5%) or a study 
involving the crew of one aircraft carrier (59.7%).15,17 
The seropositivity rates in this study were closer to 
those observed in the general population in two 
California seroprevalence studies from April, with the 
exception of the Miami Hard Rock Stadium site which 
was nearly double at 8.2% of 1,395 tests.13-14  
 
One of the main limitations of this study was the 
reported performance characteristics of the rapid POC 
antibody test to determine the presence of SARS-CoV-
2 antibodies. The Cellex Inc. qSARS-CoV-2 IgG/IgM 
rapid test used was approved under the United States 
Food and Drug Administration’s (FDA) Emergency 
Use Authorization (EUA); the test’s performance 
specifications had a reported positive agreement with 
clinical specimens of 93.8% and negative agreement 
of 96.0%.19 The negative agreement is of concern for 
areas with a low prevalence because false positive 
results could account for a large proportion of the 
positive test results. However, for higher prevalence 
sites the even lower positive agreement may mean that 
more true positives were missed (underestimating the 
burden of disease), especially if the real-world use of 
these tests had lower sensitivity than during 
validation.21 Additional guidance after the initiation of 
this project was developed and advised using an 
orthogonal testing algorithm for persons testing 
positive by antibody tests, which could lead to 
improved positive predictive value of this test.22 It 
should be noted, few antibody tests are POC, available 
at-scale, and have an FDA EUA, making them not 
feasible for this testing mission, nor possible for an 
orthogonal antibody testing algorithm.  
 
One remaining limitation of this study is its lack of 
generalizability as it focused entirely on healthcare 
workers and first responders in Florida, which limits 
the ability to extrapolate our data, as the risk of 
infection in this cohort is not likely the same as in the 
general population .13-14  However, with the expansion 
of these same testing sites to the general public on June 
4, 2020, future analyses may allow for generalizability 
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and comparison between the general public and this 
occupational group.  
 
As part of this evaluation, we were able to show that 
POC SARS-CoV-2 antibody testing was feasible at-
scale, sustainable, and replicable. It is worth noting 
that the resources needed, including labor (most sites 
needed multiple personnel for phlebotomy, data entry, 
testing, etc.) and materials (test kits, personal 
protective equipment, venipuncture supplies, and 
more) each and every day, are not trivial. One big 
benefit of these tests is that they can be performed 
outside of clinical laboratories.  If the test could be 
shown to achieve similar results using fingerstick 
instead of venipuncture, it would dramatically reduce 
the skilled resources needed to conduct widespread 
screening. This use of drive-thru testing sites and rapid 
antibody tests may be one potential way for agencies 
to meet some of the demands for SARS-CoV-2 
serological testing.23-26 
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Supplemental Table 1.   Logistic Regression Model adjusting for all demographics and testing sites in one model for 
SARS-CoV-2 point-of-care (POC) antibody seropositivity, Florida, May-June 2020* 
 
 
Demographic/Testing Site  Adj. Odds Ratio 
 
95% Confidence Intervals 
Race/Ethnicity    
   White non-Hispanic Ref -- -- 
   Black non-Hispanic 1.64 1.08 2.49 
   Hispanic/Latino(a) 2.19 1.51 3.18 
   Haitian/Creole 3.50 1.30 9.42 
  Other† 1.57 0.82 3.04 
Age Group    
   17-29 Ref -- -- 
   30-39 0.73 0.45 1.17 
   40-49 0.66 0.40 1.07 
   50-59 1.01 0.64 1.59 
   60-69 1.07 0.63 1.82 
   70-89 1.77 0.75 4.20 
Sex at Birth    
   Female 1.04 0.77 1.39 
   Male Ref -- -- 
Testing Site    
   Jacksonville Ref -- -- 
   Palm Beach 0.78 0.39 1.54 
   Miami Hard Rock 2.24 1.49 3.39 
   Miami Beach 1.04 0.50 2.16 
   Orlando 0.98 0.64 1.50 
* The likelihood ratio rejected the null hypothesis (X2=84.08; P<0.0001) for the logistic 
regression model’s goodness of fit. McFadden’s pseudo R2 for the model was 0.05. †Persons 
of other race/ethnicity were individuals who identified as either “other” as a race or identified 
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